Janus Kinase Inhibitor
Filgotinib shows dose-dependent risks for malignancy, mortality in older adults with RA
A long-term safety analysis of filgotinib for moderate-to-severe rheumatoid arthritis demonstrated potential dose-dependent risks for herpes zoster, malignancies and all-cause mortality in patients aged 65 and older, according to data.
VIDEO: Studies show no increased risk of cancer, CV events with JAK inhibitors
In this video, Raymond Cross, MD, spoke with Healio about several studies assessing the safety and efficacy of JAK inhibitors in patients with IBD presented at Digestive Disease Week 2024.
TRIUMPH: 58% of acute severe UC patients responded ‘within 2 days’ of starting Xeljanz
WASHINGTON — Nearly 60% of patients with acute severe ulcerative colitis responded to Xeljanz 10 mg twice daily by day 7, with one-third of patients in steroid-free remission by 6 months, according to interim analysis data presented here.
Beneath the Surface: Addressing JAK inhibitor safety in alopecia with Brett King, MD, PhD
Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.
Ruxolitinib cream 1.5% effective, safe for adolescents with atopic dermatitis
Ruxolitinib cream 1.5% was safe and well tolerated up for the short- and long-term treatment of atopic dermatitis in adolescents, according to an analysis of two phase 3 studies.
‘Efficacy will lead’ as first-line JAK inhibitor use picks up in moderate to severe UC
Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results.
VIDEO: JAK inhibitors usher new era in alopecia areata treatment
SAN DIEGO — In this Healio video perspective here at the American Academy of Dermatology, Brett King, MD, PhD, FAAD, discusses how new Janus kinase inhibitors have changed the paradigm of alopecia areata treatment.
JAK inhibitors have ‘untapped potential’ in treatment of inflammatory skin diseases
MIAMI BEACH, Fla. — Janus kinase inhibitors have a unique mechanism of action, giving them the potential to push the boundaries of efficacy in the treatment of inflammatory skin diseases, according to a speaker at South Beach Symposium.
VIDEO: Recent clinical trial results, ongoing research in polymyalgia rheumatica
In this video, Sebastian E. Sattui, MD, MS, discusses exciting research on polymyalgia rheumatica.
Meet the Board: Michael S. Blaiss, MD
Careers in allergy and asthma can take physicians into private, corporate or academic work as well as into professional organizations. Michael S. Blaiss, MD, a new member of Healio’s Allergy/Asthma Peer Perspective Board, has done it all.